Immunomodulation during penetrating keratoplasty. Current status and perspectives;Immunmodulation bei perforierender keratoplastik. Stand und perspektiven

Ophthalmologe

Volumn 100, Issue 12, 2003, Pages 1036-1044

  Pleyer, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immune modulation; Keratoplasty; Prevention; Transplant rejection

Indexed keywords

15 DEOXYSPERGUALIN; ACICLOVIR; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; RAPAMYCIN; RIMEXOLONE; SANDIMMUN OPTORAL; TACROLIMUS; UNCLASSIFIED DRUG;

CORNEA TRANSPLANTATION; CORTICOSTEROID THERAPY; CYTOPENIA; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEMATURIA; HEPATITIS; HERPES SIMPLEX KERATITIS; HIGH RISK PATIENT; HIRSUTISM; HUMAN; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INFECTION; LEUKOPENIA; NEUTROPENIA; PENETRATING KERATOPLASTY; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TRANSPLANTATION TOLERANCE; TREMOR;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANIMALS; ANTIVIRAL AGENTS; AZATHIOPRINE; CLINICAL TRIALS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATITIS, HERPETIC; KERATOPLASTY, PENETRATING; METHOTREXATE; MICE; MULTICENTER STUDIES; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TACROLIMUS;

EID: 0347854363     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-003-0954-4     Document Type: Review

References (88)

1. Akova YA, Onat M, Duman S (1999) Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. Ocul Immunol Inflamm 7:51-60
2. Armitage J, Dick A, Bourne WM (2003) Prediction endothelial cell loss and long-term corneal graft survival. Invest Ophthal Vis Sci 44:3326-3331
3. Ayliffe W, McLeoad D, Hutchinson IV (1992) Tolerance to rat corneal allografts induced by anti-CD4 antibodies. Invest Ophthalmol Vis Sci 33:831-836
4. Bach JF, Fracchia GN, Chatenoud L (1993) Safety and efficacy of therapeutic monoclonal antibodies in clinical trials. Immunol Today 14:421-425
5. Barker NH, Henderson TR, Ross CA et al. (2000) Current Australian practice in the prevention and management of corneal allograft rejection. Clin Experiment Ophthalmol 28:357-360
6. Beato M (1989) Gene regulation by steroid hormones. Cell 56:335-344
7. Benelli U, Lepri A, Del Tacca M, Nardi M (1996) FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 12:425-431
8. Bertelmann E, Knapp S, Rieck P et al. (2003) Transkornealer-parakornealer Penetrationsweg für lokal applizierter Pharmaka am Auge - Mycophenolat Mofetil als Modellsubstanz. Ophthalmologe 100:696-701
9. Bertelmann E, Reinhard T, Pleyer U (im Druck) Stand der Immunprophylaxe und -therapie bei perforierender Keratoplastik: Eine Umfrage bei Mitgliedern der Sektion Kornea der DOG. Ophthalmologe
10. Bertelmann E, Jaroszewski J, Pleyer U (2002) Corneal allograft rejection: current understanding: 2. Clinical implications. Ophthalmologica 216:2-12
11. Buxton JN, Apisson JG, Hoeffle FB (1969) Corticosteroids in 100 keratoplasties. Am J Ophthalmol 67:46-51
12. CCTS: The collaborative corneal transplantation studies (1992) Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 110:1392-1403
13. Cockerham G (2001) Primary graft failure caused by herpes simplex virus type 1. Cornea 20:774-775
14. Coster DJ (1989) Mechanisms of corneal cornea@ graft failure the erosion of corneal privilege. Eye 2:251-262
15. Donish PC, Cavanagh D, Boruchoff SA, Dohlman CH (1981) Posterior subcapsular cataract induced by topical corticosteroids following keratoplasty for keratoconus. Ann Ophthalmol 13:12-15
16. Ensley RD, Bristow MR, Olsen SL et al. (1993) The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56:75-82
17. European Mycophenolat Mofetil Cooperative Study Group (1995) Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 345:1321-1325
18. Goichet-Bonnat L, Chembla P, Pouliquen Y (1987) Cyclosporin A eye drops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results. J Fr Ophthalmol 10:213-217
19. Grant D, Kneteman N, Tchervenkov J et al. (1999) Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neural and sandimmune for liver transplantation (NOF-8). Transplantation 67:1133-1137
20. He YG, Mellon J, Niederkorn JK (1996) The effect of oral immunization on cornea allograft survival. Transplantation 61:920-926
21. Hoffmann F, Kruse HA, Meinhold H et al. (1994) Interleukin-2 receptor-targeted therapy by monoclonal antibodies in the rat corneal graft. Cornea 13:440-446
22. Holbach LM, Bayer J, Seitz B et al. (1993) Herpes simplex-Keratitis: zur Langzeitprognose von Ersttransplantaten nach perforierender Keratoplastik. Ophthalmologe 90:698-702
23. Hikita N, Lopez JS, Chan CC et al. (1997) Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 38:901-909
24. Hill JC (1989) The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 107:506-510
25. Hill C, Maske R, Watson P (1991) Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology 98:329-333
26. Hill C (1994) Systemic cyclosporine in high risk keratoplasty. Ophthalmology 101:128-133
27. Ippoliti G, Fronterrè A (1989) Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 21:3133-3134
28. Knapp S, Bertelmann E, Hartmann C et al. (2003) Intraocular availability of topically applied Mycophenolate Mofetil in rabbits. J Ocul Pharmacol Ther 19:181-192
29. Larkin DFP, Oral HB, Ring CJA et al. (1996) Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 61:363-370
30. Larkin F, Lightman S (1999) Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370-374
31. Leibowitz HM, Kupferman A (1976) Kinetics of topically administered prednisolone acetate. Arch Ophthal 94:1387-1389
32. Liekfeld A, Jaeckel C, Pleyer U et al. (2001) Kammerwasseranalyse bei Keratoplastikpatient mit Keratitiden. Ophthalmologe 98:456-459
33. Mayer K, Reinhard T, Reis A et al. (in press) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results randomised pilot study. Greaf's Arch Clin Exp Ophthalmol
34. Medeiros M, Perez-Urizar J, Munoz R, Castaneda-Hernandz G (1999) Limited sampling model for area-under-the-curve monitoring pediatric patients receiving either Sandimmune of Neoral cyclosporin A oral formulations. Pediatr Transplant. 3:225-230
35. Meyes AL, Sugar A, Musch DC, Barnes RD (1994) Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol 112:601-607
36. Milani J, Pleyer U, Dukes A et al. (1993) Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 100:890-896
37. Mills RA, Jones DB, Winkler CR et al. (1995) Topical FK506 prevents experimental corneal allograft rejection. Cornea 14:157-160
38. Morris RE, Shorthouse R (1990) A study of the contrasting effects of cyclosporine, FK506, and rapamycin on suppression of allograft rejection. Transplant Proc 22:1638-1641
39. Mortola E, Endo Y, Ohno K et al. (1998) The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. Vet Res Commun 22:553-563
40. Newman DK, Isaacs JD, Watson PG et al. (1995) Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye 9:564-569
41. Niederkorn JY, Lang LS, Ross J et al. (1994) Promotion of corneal allograft survival with leflunomide. Invest Ophthalmol Vis Sci 35:3783-3785
42. Nishi M, Herbort CP, Matsubara M et al. (1993) Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci 34:2477-2486
43. Okada K, Sakata H, Minamoto A, Fujihara M (1996) Effect of FK506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 210:175-179
44. Olsen TW, Benegas NM, Morali S et al. (1993) Low dose rapamycin and 1S-deoxyspergualin significantly prolong allograft survival in the orthotopic rat keratoplasty model. Invest Ophthalmol Vis Sci 34:1365
45. Olsen TW, Benegas NM, Joplin AC et al. (1994) Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 112:1471-1475
46. Perry HD, Donnenfeld ED, Kanellopoulos AJ, Grossman GA (1997) Topical cyclosporin A in the management of postkeratoplasty glaucoma. Cornea 16:284-288
47. Pfau B, Kruse FE, Rohrschneider K et al. (1995) Comparison between local and systemic cyclosporine concerning the concentration in conjunctiva, aequeous humor and blood. Ophthalmologe 92:833-839
48. Pleyer U, Weidle EG, Thiel HJ (1989) The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 108:467-468
49. Pleyer U, Steuhl KP, Weidle EG et al. (1992) Corneal graft rejection: Incidence, manifestation, and interaction of clinical subtypes. Transplant Proc 24:2034-2037
50. Pleyer U, Lutz S, Jusko WJ et al. (1993) Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 34:2737-2742
51. Pleyer U, Zierhut M, Thiel HJ (1994) Antibodies as preventive/therpeutic agents in corneal graft rejection. In: Zierhut M, Pleyer U, Thiel HJ (eds) Immunology of corneal transplantation. Aeolus Press, Buren, pp 263-275
52. Pleyer U, Elkins B, Rückert D et al. (1994) Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res 13:177-181
53. Pleyer U, Milani JK, Dukes A et al. (1995) Effect of liposome encapsulated anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 35:52-61
54. Pleyer U, Bertelmann E, Rieck P et al. (2000) Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol 238:531-536
55. Pleyer U, Ritter T, Volk HD (2000) Immune tolerance and gene therapy in transplantation. Immunology today 21:12-15
56. Pleyer U, Dannowski H, Volk HD, Ritter T (2001) Corneal allograft rejection: current understanding. I. Immunobiology and basic mechanisms. Ophthalmologica 215:254-262
57. Pleyer U, Groth D, Hinz B et al. (2001) Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 73:1-7
58. Pleyer U, Bertelmann E, Rieck P, Hartmann C (2002) Outcome of penetrating keratoplasty in rheumatoid arthritis. Ophthalmologica 216:249-255
59. Pleyer U, Sherif Z (2002) Corticosteroids in ophthalmology. In: Cato ACB, Schäcke H, Asadullah K (eds) Recent advances in glucocorticoid receptor action. Ernst Schering Research Foundation, Workshop 40. Springer, Berlin Heidelberg New York Tokyo, pp 65-81
60. Pleyer U, Ritter T (2003) Gene therapy in immune mediated diseases of the eye. Prog Retin Eye Res 22:277-293
61. Pleyer U, Yang J, Knapp S et al. (2003) Effects of a selective steroid receptor agonist (SEGRA) on experimental keratoplasty. Ophthalmologe 100:27
62. Power H (1873) On transplantation of the cornea. Rep Internat Ophth Cong, London 4:172-176
63. Reinhard T, Reis A, Bohringer D et al. (2001) Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 239:367-372
64. Reis A, Reinhard T, Voiculescu A et al. (2001) Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease. Klin Monatsbl Augenheilkd 218:183-186
65. Reis A, Megahed M, Reinhard T et al. (2002) Synergism of RAD and cyclosporine A in prevention of acute rat corneal allograft rejection. Cornea 21:81-84
66. Rinne JR, Stulting RD (1992) Current practice in the prevention and treatment of corneal allograft rejection. Cornea 11:326-328
67. Ritter T, Vogt K, Rieck P et al. (1999) Adenovirus-mediated gene transfer of interleukin-4 to corneal endothelial cells and organ cultured corneas leads to high IL-4. Exp Eye Res 69:563-568
68. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U (2002) Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 988-992
69. Schäcke H, Hennekes H, Schottelius A et al. (2002) SEGRASs: a novels class of anti-inflammatory compounds. In: Cato ACB, Schäcke H, Asadullah K (eds) Recent advances in glucocorticoid. Receptor action. Corticosteroids in ophthalmology. Ernst Schering Research Foundation, Workshop 40. Springer, Berlin Heidelberg New York Tokyo, pp 357-371
70. Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immunsuppression durch Kombinationstherapie mit Basiliximab und Ciclosporin bei Hochrisikokeratoplastik. Eine Pilotstudie. Ophthalmologe 99:38-45
71. Sehgal SN (1998) Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335-340
72. Shapiro R, Fung JJ, Jain A et al. (1990) The side effects of FK506 in humans. Transplant Proc 22:41-43
73. Simon AL, Pavan-Langston D (1996) Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. Ophthalmology 103:1399-404; discussion 1404-1405
74. Sigal NH, Dumont FJ (1992) Cyclosporin A, FK506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 10:519-560
75. Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108:1838-1844
76. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group (1995) Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232
77. Sonkin PL, Baratz KH, Fronthingham R, Cobo LM (1992) Acyclovir resistant herpes simplex virus keratouveitis after penetrating keratoplasty. Ophthalmology 99:1805-1808
78. Sugar A, Bokosky JE, Meyer RF (1993) A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. Cornea 3:268-271
79. Sundmacher R, Reinhard T, Heering P (1992) Six years experience with systemic Cyclosporin A prophylaxis in high risk perforating keratoplasty patients. German J Ophthalmol 1:432-436
80. Sundmacher R, Reinhard T (1994) Cyclosporin A in high risk perforating keratoplasty. In: Zierhut M, Pleyer U, Thiel W (eds) Immunology of corneal transplantation. Aeolus Press, Amsterdam, pp 233-238
81. Tambasco FP, Cohen EJ, Nguyen LH et al. (1999) Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol 17:445-449
82. Thompson P, Xu D, Chen H, Brunette I (1993) Effect of rapamycin and cyclosporin on corneal rejection in the rat penetrating keratoplasty model. Invest Ophthalmol Vis Sci 34:1101
83. Tompson RW, Price MO, Bowers PJ, Price FW (2003) Long-term in grafts survival after penetrating keratoplasty. Ophthalmology 110:1396-1402
84. Van Gelderen EB, Van der Lelij A, Völker-Dieben HJ et al. (1999) Are cytokine patterns in aqueous humour useful in distinguishing corneal graft rejection from opacification due to herpetic stromal keratitis? Ophthalmol 99:171-82
85. Wachtlin J, Khaireddin R, Hoffmann F (in press) Gewebetypisierung bei perforierender Keratoplastik. Ophthalmologe
86. Waldmann H (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 7:407-444
87. Zhang EP, Schulte F, Bulfone-Paus S, Hoffmann F (2000) The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol 238:525-530
88. Zheng X (2002) Reactivation and donor-host transmission of herpes simplex virus after corneal transplantation. Cornea 21:90-93